In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Alzheimer disease (AD) and Parkinson disease (PD) are the most common
neurodegenerative disorders. For both diseases, early intervention is thought to be essential …

Highlights•Multiple cellular changes have been identified as being involved in AD
pathogenesis.•Studies concluded that abnormal APP processing causes Aβ-induced …

Introduction Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) has
been extensively pursued as potential disease-modifying treatment for Alzheimer's disease …

Alzheimer's disease (AD) is a very serious public health problem. Currently, there is no
effective treatment for AD. Among the many biochemical targets for AD drug development, β …

Background Advances in the treatment of brain tumours have increased the number of long‐
term survivors, but at the cost of side effects following cranial radiotherapy ranging from …

No disease-modifying therapies (DMT) for neurodegenerative diseases (NDs) have been
established, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD). It is …

Alzheimer's disease, a significant contributor to dementia, is rapidly becoming a serious
healthcare concern in the 21 st century. The alarming number of patients with Alzheimer's …

Twelve years after publication of the first WFSBP consensus paper on the biomarkers of
dementia disorders (Wiltfang et al. 2005), the WFSBF Task Force now takes the opportunity …

Alzheimer's disease (AD) is the most common form of dementia worldwide, affecting over 35
million people and accounting for two thirds of the dementia patients. Unfortunately, despite …